Efficacy and safety of Qianlieshutong capsule in the treatment of type III prostatitis (TCM syndrome of damp-heat and blood-stasis obstruction): a multicenter, randomized, double-blind, single simulation, positive drug parallel controlled clinical trial

Beijing Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. The diagnosis criterias of type III prostatitis are met;
•2. The diagnosis criterias of TCM syndrome of damp-heat and blood-stasis obstruction are met;
•3. Aged >= 18 and <= 50 years;
•4. Chronic prostatitis symptom index (NIH CPSI) is more than 10, and pain score was >= 4;
•5. Patients sign informed consent voluntarily.

•1. Patients have weak waist and knees and are afraid of cold;
•2. Patients diagnosed of benign prostatic hyperplasia, acute urinary retention, urethral stricture, epididymitis, seminal vesicle inflammation, severe neurosis, sexually transmitted diseases, bladder tumor, prostate cancer, and urinary male reproductive system tuberculosis;
•3. Patients with pain diseases of lower abdomen, perineum, lumbosacral and other parts caused by non prostatitis;
•4. Patients with severe cardiovascular, cerebrovascular, liver and kidney, endocrine system, hematopoietic system, mental and nervous system and other primary diseases, liver function ALT and / or AST were 1.5 times higher than the upper limit of normal value, and renal function (CR) was greater than the upper limit of normal value;
•5. Suspected or confirmed history of alcohol and drug abuse;
•6. Urinary tract infection;
•7. Refractory patients treated with a - blockers;
•8. Postural hypotension patients;
•9. Allergic to the trial drug and its components;
•10. Patients who had pelvic surgery within 3 months;
•11. Patients who have used drugs or other related treatment for chronic prostatitis in recent 2 weeks;
•12. Patients who have participated in other clinical trials in recent 3 months;
•13. Patients who have birth planning during the period of medication and within one month after the end of medication;
•14. Patients who are considered unsuitable for clinical trials by researchers.

发起方

Beijing Hospital